ASK Pharm makes Chi­na rights deal; Uni­cy­cive re­sub­mits kid­ney drug af­ter CRL
Plus, news about Har­bour Bio­Med, Omeros, Gilead, Re­pare Ther­a­peu­tics, Vac­cinex and Fore­see Phar­ma­ceu­ti­cals.
💵 ASK Pharm nabs Chi­na rights to pan-RAS in­hibitor:
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Gilead­'s her­pes deal; FDA ap­provals for Boehringer, Roche
Al­tim­mune ad­vances in MASH; New Chi­na obe­si­ty biotech; Ipsen Phase 2 fail
Sub­cu­ta­neous Ry­bre­vant; Kalaris shares nAMD da­ta; Pyx­is dis­ap­points
Client Engagement Mgr - Life Sciences Strategy & Intelligence
Fed­er­al judge blocks 340B drug pric­ing pi­lot ahead of Jan. 1 ef­fec­tive date
Gene edit­ing's search for a 'holy grail' has led to an ex­plo­sion of tools, but few cures
Ul­tragenyx, Mereo crash on late-stage bone dis­ease fail­ure
Nido Bio to wind down af­ter un­der­whelm­ing Phase 2 da­ta
Gen­mab ends de­vel­op­ment of Phase 3 lung can­cer as­set that BioN­Tech ditched ear­li­er
The End­points win­ners and losers list: Who was up and who was down in 2025
Bioscience & Technology Business Center